HRMY stock forecast, quote, news & analysis

Key Takeaways

• Harmony Biosciences (HRMY) has declined roughly 13.8% over the last 30 days, falling from a closing price of $39.92 on October 5, 2026, to an intraday level near $34.42 in early November.
• Over the last quarter, the stock is down about 11%, retreating from levels around $38.78 in early August after peaking near $43 in early September.
• A planned CEO transition announced on October 12, 2026, triggered a sell-off of more than 5% in a single session despite reaffirmed full-year revenue guidance.
• Third-quarter 2026 results reported in early November showed WAKIX net revenue of $268.9 million, up 12% year over year, but slightly below consensus and paired with a year-over-year decline in earnings per share.
• Broader weakness across the pharmaceuticals sector and a mixed analyst landscape, including Sell and Hold ratings with lower price targets, added pressure during the period.
• You can review additional detail on this ticker's Price Targets, Earnings, and Forecast on dedicated pages.
• Explore Trending AI Robots to see how AI-driven trading strategies are currently positioning across the market.

Harmony Biosciences (HRMY) Company Overview and Market Position

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company headquartered in Plymouth Meeting, Pennsylvania, focused on developing and commercializing therapies for patients living with rare neurological diseases. Its lead product, WAKIX (pitolisant), is the first and only FDA-approved, non-scheduled treatment for excessive daytime sleepiness and cataplexy in adults and pediatric patients six years and older with narcolepsy.

WAKIX has become the company's flagship commercial asset, with Harmony targeting more than $1 billion in full-year 2026 net revenue. Beyond WAKIX, the company is advancing a neuroscience pipeline led by BP-205, an investigational orexin-2 receptor agonist, along with lifecycle programs for pitolisant and other rare-CNS assets. Investors follow HRMY closely because of the durability of the WAKIX franchise, the pipeline's long-term potential, and the company's sizable cash position, which supports strategic business development.

Harmony Biosciences (HRMY) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, HRMY shares have fallen approximately 13.8%. The stock closed at $39.92 on October 5, 2026, and traded near $34.42 by early November, reflecting a steady downward drift punctuated by sharper single-day declines in mid-October and again in early November.

The quarterly picture is similarly negative but less severe. From a close near $38.78 on August 4, 2026, the stock is down roughly 11% over the trailing three months. Notably, the quarter included a strong early stretch: HRMY climbed to an intraday high above $43 in early September before momentum reversed. The subsequent pullback, driven by leadership-change headlines, sector rotation, and a softer earnings reaction, has left shares well below their late-summer peak.

What Drove HRMY Stock Price in the Last 30 Days

The most consequential catalyst of the period was the October 12, 2026, announcement of a planned leadership transition. The company said President and CEO Jeffrey M. Dayno, M.D., would retire at the end of 2026, with COO Peter Anastasiou set to become CEO effective January 1, 2027. Although Harmony characterized the move as a planned succession and reaffirmed its 2026 WAKIX revenue guidance of $1.0 billion to $1.04 billion, investors reacted negatively, sending shares down more than 5% that session.

Weakness in late October was compounded by broad declines across the pharmaceuticals sub-sector, with HRMY closing near session lows during a period of market-wide selling pressure. The final leg lower arrived with third-quarter 2026 results reported on November 4, 2026. WAKIX net revenue of $268.9 million grew 12% year over year, but it came in modestly below analyst expectations, while net income declined to $48.2 million, or $0.81 per diluted share, from $50.9 million, or $0.87 per share, a year earlier, partly reflecting higher royalty and milestone costs.

Analyst sentiment also remained divided. While several firms maintained Buy or Outperform ratings, Bank of America Securities reiterated a Sell rating with a $30 price target, and other institutions maintained Hold ratings with price targets near or below the prevailing share price, reinforcing a cautious near-term tone.

What Drove HRMY Stock Performance Over the Last Quarter

The broader three-month narrative reflects a stock that rallied early and then gave back its gains. HRMY rose into early September on continued strength in the WAKIX franchise and enthusiasm around its pipeline, including BP-205 single-ascending-dose data and preparations for pitolisant lifecycle programs. However, the rally was not sustained.

The October CEO-transition announcement introduced execution and succession uncertainty, even as management emphasized continuity in strategy. Around the same time, softer market conditions for biopharmaceutical names and lingering concerns about WAKIX's long-term exclusivity and generic competition weighed on sentiment. The early-November earnings report, which highlighted solid demand but higher operating costs and an EPS decline, reinforced the shift toward a more defensive posture among investors over the trailing quarter.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a broader platform of hundreds of bots trading thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving visitors a focused view of strategies that are currently standing out. These bots vary considerably in trading strategy, holding timeframe, and performance metrics, so the section is designed to help traders compare different approaches rather than provide a single recommendation. Investors interested in automated, data-driven trading can explore the page to see which AI strategies are gaining traction across the market.

HRMY Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several factors are likely to shape HRMY's trajectory. The formal handoff of the CEO role to Peter Anastasiou on January 1, 2027, and any strategic updates that follow will be closely monitored. Investors will also track whether WAKIX continues to deliver consistent net patient additions and whether the company can sustain its path toward exceeding $1 billion in annual revenue.

Clinical and regulatory milestones remain central. Key watchpoints include the Pitolisant GR New Drug Application, which carries a PDUFA date of April 1, 2027, Phase 1b data for BP-205 in sleep-deprived healthy volunteers expected in the first quarter of 2027, and the initiation of Phase 2 studies planned for mid-2027. Ongoing patent litigation over the pitolisant franchise, with rulings expected around early 2027, will also influence the long-term revenue outlook. As with any biopharmaceutical investment, clinical setbacks, regulatory delays, and shifting payer dynamics remain meaningful risks.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations